89547-15-9

Usage

Uses

2-Hexadecyl-octadecanoic Acid is a branched saturated fatty acid.

Upstream product

• 138950-58-0 dihexadecylmalonic acid diethyl ester 
• 41433-81-2 diethyl 2-hexadecylmalonate 
• 112-82-3 hexadecanyl bromide 
• 544-77-4 1-iodohexadecane 
• 57-11-4 stearic acid 
• 4471-14-1 dihexadecylmalonic acid 

Downstream Products

• 1223421-17-7 6,6'-bis-O-(2-hexadecyloctadecanoyl)-2,3,4,2',3',4'-hexabenzyl-α,α'-trehalose 
• 69472-23-7 2-Hexadecyloctadecan-1-ol 

Relevant academic research and scientific papers

Tris(2-aminoethyl)amine-based α-branched fatty acid amides - Synthesis of lipids and comparative study of transfection efficiency of their lipid formulations This article is dedicated to Professor Gerald Brezesinski on occasion of his 65th birthday.

The synthesis of a new class of cationic lipids, tris(2-aminoethyl)amine-based α-branched fatty acid amides, is described resulting in a series of lipids with specific variations in the lipophilic as well as the hydrophilic part of the lipids. In-vitro structure/transfection relationships were established by application of complexes of these lipids with plasmid DNA (pDNA) to different cell lines. The α-branched fatty acid amide bearing two tetradecyl chains and two lysine molecules (T14diLys) in mixture with the co-lipid 1,2-di-[(9Z)-octadec-9-enoyl]-sn-glycero-3-phosphoethanolamine (DOPE) (1/2, n/n) exhibits effective pDNA transfer in three different cell lines, namely Hep-G2, A549, and COS-7. The presence of 10% serum during lipoplex incubation of the cells did not affect the transfection efficiency. Based on that, detailed investigations of the complexation of pDNA with the lipid formulation T14diLys/DOPE 1/2 (n/n) were carried out with respect to particle size and charge using dynamic light scattering (DLS), ζ-potential measurements, and transmission electron microscopy (TEM). Additionally, the lipoplex uptake was investigated by confocal laser scanning microscopy (CLSM). Overall, lipoplexes prepared from T14diLys/DOPE 1/2 (n/n) offer large potential as lipid-based polynucleotide carriers and further justify advanced examinations.

Development of vizantin, a safe immunostimulant, based on the structure-activity relationship of trehalose-6,6′-dicorynomycolate

Vizantin, 6,6′-bis-O-(3-nonyldodecanoyl)-α,α′- trehalose, was developed as a safe immunostimulator on the basis of a structure-activity relationship (SAR) study with trehalose 6,6′- dicorynomycolate (TDCM). It was possible to synthesize vizantin on a large scale more easily than in the case of TDCM, and the compound exhibited more potent prophylactic effect on experimental lung metastasis of B16-F0 melanoma cells. Because vizantin stimulated human macrophages, it is a promising candidate for clinical application.

TREHALOSE COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL PRODUCT CONTAINING THE COMPOUND

It is an object of the present invention to provide a trehalose compound having high immunopotentiating activity and low toxicity. The trehalose compound is represented by formula (1). (In the formula, X and X' each represents a phenyl, a naphtyl, R1-CHR1- (wherein R1 and R2 each represents a C7-C21 alkyl group or the like) or the like; and n and n' each independently represents an integer of 0-3). The compound exhibits a high activating effect on macrophages and neutrophils.

TREHALOSE COMPOUND, PROCESS FOR PRODUCTION OF THE COMPOUND, AND IMMUNO-STIMULATIVE AGENT COMPRISING THE COMPOUND

An object of the present invention is to provide a novel trehalose compound that exhibits excellent immunostimulating activity and that can be supplied in a large quantity in an industrial scale, and a method for producing the trehalose compound, wherein

Sialic acid-containing glycolipid derivatives

Sialic acid- containing glycolipid derivatives represented by the following general formula, their production method, and the particulate carriers that contain as a constituent the sialic acid-containing glycolipid derivative(s). STR1 wherein represents t